FDA Off-Label Policy Should Allow Dissemination With Disclaimer – CHC

FDA's off-label drug information policy should allow unfettered dissemination provided the manufacturer discloses that the information has not been approved by FDA, the Coalition for Healthcare Communication said in comments submitted to the agency